
Nephrocare Health Services IPO
- Issue price
- ₹460
- Listing price
- ₹490
- +6.52%
- Current price
- ₹651.05
- +41.53%
- Subscribed
- 13.96x
- Issue size
- ₹871.05 Cr
- Listed on
- 17 Dec 2025
IPO timeline
- Opens10 DecWed
- Closes12 DecFri
- Allotment15 DecMon
- Refunds16 DecTue
- Demat credit16 DecTue
- Listing17 DecWed
Issue details
- Price band
- ₹438 – ₹460 per share
- Issue size
- ₹871.05 Cr
- Fresh issue
- Not available
- Offer for sale
- Not available
- Issue type
- Fresh capital cum OFS
- Face value
- ₹2 per share
- Lot size
- 32 shares
- Minimum investment
- ₹14,720
- Listing on
- BSE & NSE
- Exchange code
- NEPHROPLUS · 7492
This issue combines a fresh issue and an offer for sale. The amounts for each part are not available in our data; see the offer document for the split.
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 32 | ₹14,720 |
| Retail (Max) | 13 | 416 | ₹1,91,360 |
| S-HNI (Min) | 14 | 448 | ₹2,06,080 |
| B-HNI (Min) | 68 | 2,176 | ₹10,00,960 |
Reservation
- QIB
- 94,29,865 shares (50.00% of the Offer)
- NII
- 28,28,960 shares (15.00% of the Offer)
- Retail
- 66,00,907 shares (35.00% of the Offer)
- Employee
- 83,532 shares (0.44% of the Offer)
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on KFin Technologies- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 15 Dec 2025
- Refunds initiated
- 16 Dec 2025
- Shares credited to demat
- 16 Dec 2025
- Listing
- 17 Dec 2025
Grey market premium (GMP)
- Current GMP
- ₹20
- +4.00%
- Estimated listing price
- ₹480
- Issue price ₹460
- Kostak rate
- ₹0
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB27.47x
- NII (HNI)24.27x
- Retail2.31x
- Employee2.67x
| Category | Shares offered | Shares bid for | Subscribed |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 36,78,793 | 10,10,69,088 | 27.47x |
| Non-Institutional Investors (NII) | 28,86,270 | 7,00,51,008 | 24.27x |
| bNII — bids above ₹10 Lakh | 19,24,180 | 5,73,66,080 | 29.81x |
| sNII — bids ₹2 Lakh to ₹10 Lakh | 9,62,090 | 1,26,84,928 | 13.18x |
| Retail Individual Investors (RII) | 67,34,630 | 1,55,38,304 | 2.31x |
| Employee | 88,161 | 2,35,136 | 2.67x |
| Total | 1,33,87,854 | 18,68,93,536 | 13.96x |
Financials
- P/E Ratio
- 162.19
- EPS (₹)
- 2.84
- RoCE
- 18.67%
- RoNW
- 13.19%
- PAT Margin
- 8.88%
Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.
| Period ended | 30 Mar 25 | 31 Mar 24 | 31 Mar 24 |
|---|---|---|---|
| Revenue | 483.97 | 769.92 | 574.72 |
| OPM % | |||
| EBITDA | 110.31 | 166.64 | 99.66 |
| Net Profit | 14.23 | 67.10 | 35.13 |
| Debt | 207.04 | 225.80 | 243.37 |
| Assets | 1,193.68 | 996.46 | 806.02 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Nephrocare Health Services This IPO | ₹871.05 Cr | 162.19 | 13.19% | 8.88% | 13.96x | +6.52% |
| Ellenbarrie Industrial Gases Mainboard · listed 1 Jul 2025 | ₹852.53 Cr | 67.69 | 24.97% | 23.90% | 22.47x | +21.50% |
| Sudeep Pharma Mainboard · listed 28 Nov 2025 | ₹895 Cr | 53.55 | 27.88% | 27.63% | 93.72x | +23.10% |
| Suraksha Diagnostic Mainboard · listed 6 Dec 2024 | ₹846.25 Cr | 74.89 | 14.09% | 10.57% | 1.27x | -0.68% |
| Park Medi World Mainboard · listed 17 Dec 2025 | ₹920 Cr | 63.52 | 13.19% | 8.88% | 8.1x | -1.98% |
| Molbio Diagnostics Mainboard · listed 17 Aug 2026 | ₹939.7 Cr | 56.67 | 14.55% | 11.28% | 70.26x | +21.44% |
| Fusion CX Mainboard · listed 22 Oct 2026 | ₹702 Cr | 18.73 | 9.12% | 11.36% | 4.45x | +5.54% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Nephrocare Health Services plans to use the money raised, as stated in the offer document.
- BRLMs fees and commissions (including underwriting commission, brokerage and selling commission)
- Fees payable to the Registrar to the Offer
- Selling commission/processing fee for SCSBs and Bankers to the Offer, fee payable to the Sponsor Bank for Bids made by RII using UPI, brokerage and selling commission and bidding charges for the Members of the Syndicate, Registered Brokers, RTAs and CDPs
- Advertising and marketing expenses
- Listing fees, SEBI filing fees, BSE and NSE processing fees, book building software fees
- Other regulatory expenses
- Printing and stationery expenses
- Fees payable to the legal counsel
- Fees payable to other advisors to the Offer, including but not limited to Statutory Auditors, independent chartered accountant, industry expert
- Miscellaneous
About Nephrocare Health Services
Nephrocare Health Services Limited is a healthcare-focused company established with the objective of providing specialised kidney care services across India. The company was founded by experienced medical professionals and healthcare entrepreneurs who identified the growing need for quality and accessible dialysis treatment. Over the years, it has expanded its presence by setting up centres in hospitals as well as standalone units, building a network that caters to patients suffering from chronic kidney diseases. With a strong focus on clinical quality and patient care, the company has developed a reputation for reliable and standardised treatment protocols. The company primarily offers dialysis services, including haemodialysis and related renal care treatments, supported by trained medical staff and modern equipment. Its business model is asset-light and partnership-driven, where it collaborates with hospitals to operate dialysis centres within their premises, reducing capital expenditure while expanding reach. Revenue is generated through long-term service agreements and patient volumes. Promoted by professionals with domain expertise, Nephrocare focuses on operational efficiency, affordability, and scalability, aiming to address the rising demand for kidney care services in both urban and semi-urban regions.
Promoters and shareholding
Bessemer Venture Partners Trust, Edoras Investment Holdings Pte.Ltd, Healthcare Parent Ltd, Investcorp Growth Opportunity Fund, Investcorp Pvt.Equity Fund II, Vikram Vuppala
- Promoter holding, pre-issue
- 78.9%
- Promoter holding, post-issue
- 71.49%
Registrar, lead managers and documents
Company contact
Nephrocare Health Services Ltd. Address 5 th Floor, D Block, iLabs Centre, Plot 18, Software Units Layout, Survey No. 64, Madhapur, Shaikpet, Hyderabad, Telangana, 500081
+91 40 4240 8039
cs@nephroplus.comNephrocare Health Services IPO: common questions
1.When does the Nephrocare Health Services IPO open and close?
The Nephrocare Health Services IPO opens on 10 Dec 2025 and closes on 12 Dec 2025.
2.What is the price band of the Nephrocare Health Services IPO?
The price band is ₹438 – ₹460 per share, with a lot size of 32 shares and a minimum investment of ₹14,720.
3.What is the size of the Nephrocare Health Services IPO?
The issue size is ₹871.05 Cr (Fresh capital cum OFS).
4.What is the GMP of the Nephrocare Health Services IPO?
The last reported grey market premium is ₹20 per share as of 11 Dec 2025, 12:00 PM IST. GMP is unofficial and changes frequently.
5.When is the Nephrocare Health Services IPO allotment?
The basis of allotment is expected on 15 Dec 2025. Allotment status can be checked with the registrar, KFin Technologies Limited.
6.When will the Nephrocare Health Services IPO list?
The shares listed on 17 Dec 2025 on BSE & NSE.
7.Who is the lead manager of the Nephrocare Health Services IPO?
The book running lead managers are ICICI Securities, Ambit Capital, IIFL Capital Services Limited, and the registrar is KFin Technologies Limited.
8.What will the money raised in the Nephrocare Health Services IPO be used for?
As stated in the offer document, the proceeds are for: BRLMs fees and commissions (including underwriting commission, brokerage and selling commission); Fees payable to the Registrar to the Offer; Selling commission/processing fee for SCSBs and Bankers to the Offer, fee payable to the Sponsor Bank for Bids made by RII using UPI, brokerage and selling commission and bidding charges for the Members of the Syndicate, Registered Brokers, RTAs and CDPs; Advertising and marketing expenses; Listing fees, SEBI filing fees, BSE and NSE processing fees, book building software fees.
9.How can my company launch an IPO like Nephrocare Health Services?
Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393